Patient-reported outcomes (PROs) in cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC) treated with enfortumab vedotin (EV) alone or in combination with pembrolizumab (P) in the phase 1b/2 EV-103 Cohort K study.

被引：0
|
作者：
Milowsky, Matthew I.
O'Donnell, Peter H.
Hoimes, Christopher J.
Petrylak, Daniel P.
Flaig, Thomas W.
Moon, Helen H.
Friedlander, Terence W.
Mar, Nataliya
McKay, Rana R.
Srinivas, Sandy
Gravis, Gwenaelle
Ramamurthy, Chethan
Bupathi, Manojkumar
Bracarda, Sergio
Wright, Phoebe
Carret, Anne-Sophie
Yu, Yao
Matsuda, Tara
Kataria, Ritesh S.
Rosenberg, Jonathan E.
机构：
[1] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27515 USA
[2] Univ Chicago, Chicago, IL 60637 USA
[3] Duke Univ, Duke Canc Inst, Durham, NC USA
[4] Yale Canc Ctr, New Haven, CT USA
[5] Univ Colorado, Comprehens Canc Ctr, Aurora, CO USA
[6] Kaiser Permanente Southern Calif Reg, Hematol Oncol, Riverside, CA USA
[7] Univ Calif San Francisco, Med Ctr, San Francisco, CA USA
[8] Univ Calif Irvine, Orange, CA 92668 USA
[9] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA
[10] Stanford Univ, Med Ctr, Stanford, CA 94305 USA
[11] Inst Paoli Calmettes, Marseille, France
[12] Univ Texas Hlth, MD Anderson Canc Ctr, San Antonio, TX USA
[13] Rocky Mt Canc Ctr, Littleton, CO USA
[14] Azienda Osped Santa Maria, Terni, Italy
[15] Seagen Inc, Bothell, WA USA
[16] Astellas Pharma Inc, Northbrook, IL USA
[17] Merck & Co Inc, Rahway, NJ USA
[18] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[19] Weill Cornell Med Coll, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
439
引用
收藏
页数：1
相关论文
共 31 条
  • [1] Study EV-103 Cohort K: Antitumor activity of enfortumab vedotin (EV) monotherapy or in combination with pembrolizumab (P) in previously untreated cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC)
    Rosenberg, J. E.
    Milowsky, M.
    Ramamurthy, C.
    Mar, N.
    Mckay, R. R.
    Friedlander, T.
    Ferrario, C.
    Bracarda, S.
    George, S.
    Moon, H.
    Geynisman, D.
    Petrylak, D. P.
    Borchiellini, D.
    Burgess, E. F.
    Rey, J. P. Maroto
    Carret, A-S.
    Yu, Y.
    Guseva, M. V.
    Moreno, B. Homet
    O'Donnell, P. H.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1441 - S1441
  • [2] Enfortumab vedotin (EV) alone or in combination with pembrolizumab (P) in previously untreated cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer (la/mUC): Subgroup analyses of confirmed objective response rate (cORR) from EV103 cohort K.
    O'Donnell, Peter H.
    Rosenberg, Jonathan E.
    Hoimes, Christopher J.
    Petrylak, Daniel P.
    Milowsky, Matthew I.
    Mckay, Rana R.
    Srinivas, Sandy
    Friedlander, Terence W.
    Ramamurthy, Chethan
    Bilen, Mehmet Asim
    Burgess, Earle F.
    Mar, Nataliya
    Moon, Helen
    Geynisman, Daniel M.
    George, Saby
    Carret, Anne-Sophie
    Yu, Yao
    Guseva, Maria
    Moreno, Blanca Homet
    Flaig, Thomas W.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [3] Study EV-103: New randomized cohort testing enfortumab vedotin as monotherapy or in combination with pembrolizumab in locally advanced or metastatic urothelial cancer.
    Mar, Nataliya
    Friedlander, Terence W.
    Hoimes, Christopher J.
    Flaig, Thomas W.
    Bilen, Mehmet Asim
    Balar, Arjun Vasant
    Henry, Elizabeth
    Srinivas, Sandy
    Rosenberg, Jonathan E.
    Petrylak, Daniel Peter
    Burgess, Earle Frederick
    Merchan, Jaime R.
    Tagawa, Scott T.
    Carret, Anne-Sophie
    Steinberg, Joyce Leta
    Chaney, Marya F.
    Milowsky, Matthew, I
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [4] Enfortumab vedotin (EV) with or without pembrolizumab (P) in patients (pts) who are cisplatin-ineligible with previously untreated locally advanced or metastatic urothelial cancer (la/mUC): Additional 3-month follow-up on cohort K data.
    Friedlander, Terence W.
    Milowsky, Matthew I.
    O'Donnell, Peter H.
    Petrylak, Daniel P.
    Hoimes, Christopher J.
    Flaig, Thomas W.
    Mar, Nataliya
    Moon, Helen H.
    McKay, Rana R.
    Bilen, Mehmet Asim
    Borchiellini, Delphine
    Iafolla, Marco
    Carret, Anne-Sophie
    Yu, Yao
    Guseva, Maria
    Kataria, Ritesh S.
    Rosenberg, Jonathan E.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [5] Patient-Reported Outcomes in Patients With Advanced Urothelial Cancer Who Are Ineligible for Cisplatin and Treated With First-Line Enfortumab Vedotin Alone or With Pembrolizumab
    Milowsky, Matthew I.
    O'Donnell, Peter H.
    Hoimes, Christopher J.
    Petrylak, Daniel P.
    Flaig, Thomas W.
    Moon, Helen H.
    Friedlander, Terence W.
    Mar, Nataliya
    McKay, Rana R.
    Srinivas, Sandy
    Gravis, Gwenaelle
    Ramamurthy, Chethan
    Bupathi, Manojkumar
    Bracarda, Sergio
    Wright, Phoebe
    Hepp, Zsolt
    Carret, Anne-Sophie
    Yu, Yao
    Dillon, Ryan
    Kataria, Ritesh
    Beaumont, Jennifer L.
    Purnajo, Intan
    Rosenberg, Jonathan E.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (12) : 1403 - 1414
  • [6] Study EV-103: Update on durability results and long term outcome of enfortumab vedotin plus pembrolizumab in first line locally advanced or metastatic urothelial carcinoma (la/mUC).
    Friedlander, Terence W.
    Milowsky, Matthew I.
    Bilen, Mehmet Asim
    Srinivas, Sandy
    Mckay, Rana R.
    Flaig, Thomas W.
    Hoimes, Christopher J.
    Balar, Arjun Vasant
    Henry, Elizabeth
    Petrylak, Daniel P.
    Sasse, Carolyn
    Kataria, Ritesh S.
    Yu, Yao
    Carret, Anne-Sophie
    Rosenberg, Jonathan E.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [7] Study EV-103 dose escalation/cohort A: Long-term outcome of enfortumab vedotin plus pembrolizumab in first-line (1L) cisplatin-ineligible locally advanced or metastatic urothelial carcinoma (la/mUC) with nearly 4 years of follow-up
    Gupta, Shilpa
    Rosenberg, Jonathan E.
    Mckay, Rana R.
    Flaig, Thomas W.
    Petrylak, Daniel P.
    Hoimes, Christopher J.
    Friedlander, Terence W.
    Bilen, Mehmet Asim
    Srinivas, Sandy
    Burgess, Earle F.
    Merchan, Jaime R.
    Tagawa, Scott T.
    Brown, Jason R.
    Yu, Yao
    Carret, Anne-Sophie
    Wirtz, Heidi
    Guseva, Maria
    Moreno, Blanca Homet
    Milowsky, Matthew I.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [8] EV-103 study: A phase 1b dose-escalation and doseexpansion study of enfortumab vedotin in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer.
    Hoimes, Christopher J.
    Petrylak, Daniel Peter
    Flaig, Thomas W.
    Carret, Anne-Sophie
    Melhem-Bertrandt, Amal
    Rosenberg, Jonathan E.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [9] Patient-reported outcomes (PROs) from a randomized, phase 3 trial of enfortumab vedotin plus pembrolizumab (EV plus P) versus platinum-based chemotherapy (PBC) in previously untreated locally advanced or metastatic urothelial cancer (la/mUC)
    Gupta, Shilpa
    Loriot, Yohan
    Van Der Heijden, Michiel Simon
    Bedke, Jens
    Valderrama, Begona Perez
    Kikuchi, Eiji
    Flechon, Aude
    Petrylak, Daniel P.
    De Santis, Maria
    Galsky, Matt D.
    Lee, Jae-Lyun
    Swami, Umang
    Sridhar, Srikala S.
    De Giorgi, Ugo
    Wright, Phoebe
    Lu, Yi-Tsung
    Guan, Xuesong
    Dillon, Ryan
    Moreno, Blanca Homet
    Powles, Thomas
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [10] Patient-reported outcomes (PROs) from a randomized, phase 3 trial of enfortumab vedotin plus pembrolizumab (EV plus P) versus platinum-based chemotherapy (PBC) in previously untreated locally advanced or metastatic urothelial cancer (la/mUC).
    Gupta, Shilpa
    Loriot, Yohann
    van der Heijden, Michiel Simon
    Bedke, Jens
    Valderrama, Begona Perez
    Flechon, Aude
    Petrylak, Daniel P.
    De Santis, Maria
    Galsky, Matt D.
    Lee, Jae Lyun
    Swami, Umang
    Sridhar, Srikala S.
    De Giorgi, Ugo
    Wright, Phoebe
    Lu, Yi-Tsung
    Guan, Xuesong
    Dillon, Ryan
    Homet Moreno, Blanca
    Powles, Thomas
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (23_SUPPL) : 108 - 108
1234